Skip to Main Content

Paper Details

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
J Immunother Cancer
53
2019
Author NameAffiliation
Srinivasan YegnasubramanianSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • 1 - 1

Datasets

Release 1.2